SENISCA Revenue and Competitors
Estimated Revenue & Valuation
- SENISCA's estimated annual revenue is currently $2.2M per year.
- SENISCA's estimated revenue per employee is $77,500
- SENISCA's total funding is $9M.
Employee Data
- SENISCA has 29 Employees.
- SENISCA grew their employee count by 26% last year.
SENISCA's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO, Co-founder | Reveal Email/Phone |
2 | Chief Technical Officer Co-founder | Reveal Email/Phone |
3 | CEO | Reveal Email/Phone |
4 | Chief Development Officer | Reveal Email/Phone |
5 | VP Dermatology | Reveal Email/Phone |
6 | Commercial and Partnerships Director | Reveal Email/Phone |
7 | Executive Assistant | Reveal Email/Phone |
8 | Principal Scientist (Oligonucleotide Evaluation) | Reveal Email/Phone |
9 | Research Scientist | Reveal Email/Phone |
10 | CSO and R&D lead | Reveal Email/Phone |
SENISCA Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2.2M | 29 | 26% | $9.03M | N/A |
What Is SENISCA?
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics).Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence. This innovation works by restoring the ability of cells to ‘fine tune’ the expression of their genes to rejuvenate aged cells.At SENISCA, we are using this knowledge, concerning how and why cells become senescent, to develop a new generation of oligonucleotide-based interventions, to turn back the ageing clock in old cells and to target the diseases and aesthetic signs of ageing.
keywords:N/A
$9M
Total Funding
29
Number of Employees
$2.2M
Revenue (est)
26%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in Exeter
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2.3M | 29 | 21% | $3M |
#2 | $5.1M | 32 | N/A | N/A |
#3 | $8.7M | 33 | -13% | N/A |
#4 | $4M | 33 | 6% | N/A |
#5 | N/A | 36 | 16% | N/A |